SCHEMBL7220640

SCHEMBL7220640

NS(=O)(=O)c1ccc(-c2c(-c3cccc(Cl)c3)nc3ncccn23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.49
PIM1 P11309 1/20 0.49
GSK3B P49841 1/20 0.49
GAA P10253 2/20 0.48
CA2 P00918 3/20 0.47
CA1 P00915 2/20 0.47
BACE1 P56817 1/20 0.46
AKT1 P31749 1/20 0.46
AKT2 P31751 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GLA P06280 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PTGS2 P35354 5/20 0.43
PTGS1 P23219 3/20 0.43
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
KLK7 P49862 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7217037 0.87 ROCK2 (0.49) ROCK2PIM1GSK3BCA2CA1
SCHEMBL7215540 0.86 AKT1 (0.60) ROCK2PIM1GSK3BGAACA2
SCHEMBL7220427 0.82 AKT1 (0.49) ROCK2PIM1GSK3BGAACA2
SCHEMBL5260680 0.82 AKT1 (0.49) ROCK2PIM1GSK3BGAACA2
SCHEMBL7215327 0.82 AKT1 (0.49) ROCK2PIM1GSK3BGAAAKT1
SCHEMBL7220557 0.81 CA1 (0.46) ROCK2PIM1GSK3BGAACA2
SCHEMBL5263711 0.80 GAA (0.53) ROCK2PIM1GSK3BGAABACE1
SCHEMBL7222717 0.79 KDM4E (0.59) ROCK2PIM1GSK3BGAACA2
SCHEMBL7215376 0.79 PTGS2 (0.53) GAAKDM4EALDH1A1GLARAB9A
SCHEMBL5261561 0.77 KDM4E (0.59) ROCK2PIM1GSK3BGAAAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670365-B1 Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2003-12-30 US claimed
EP-1104762-B1 SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 S A L V A T LAB SA (ES) 2002-09-18 EP claimed
EP-1104762-A1 SUBSTITUTED IMIDAZO 1,2A]AZINES AS SELECTIVE INHIBOTORS OF COX-2 LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2001-06-06 EP claimed
US-6670365-B1 Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2003-12-30 US disclosed
EP-1104762-B1 SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 S A L V A T LAB SA (ES) 2002-09-18 EP disclosed
EP-1104762-A1 SUBSTITUTED IMIDAZO 1,2A]AZINES AS SELECTIVE INHIBOTORS OF COX-2 LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2001-06-06 EP disclosed